See the DrugPatentWatch profile for tigecycline

Stewardship programs can help limit tigecycline resistant infections by promoting the appropriate use of this antibiotic. Tigecycline is a last-resort antibiotic used to treat severe bacterial infections that are resistant to other antibiotics [1]. Overuse or misuse of tigecycline can lead to the development of resistant bacteria, which can make infections harder to treat and increase the risk of complications [2].

Stewardship programs aim to optimize the use of antibiotics by implementing guidelines and protocols for their prescription and administration [3]. These programs can help limit the development of antibiotic resistance by promoting the use of narrow-spectrum antibiotics, reducing the duration of therapy, and monitoring the effectiveness of treatment [4].

In the case of tigecycline, stewardship programs can help limit the development of resistance by:

* Encouraging the use of alternative antibiotics when appropriate: Stewardship programs can promote the use of other antibiotics that are less likely to cause resistance, such as beta-lactams and fluoroquinolones [5].
* Limiting the duration of therapy: Stewardship programs can recommend shorter durations of therapy for tigecycline, which can reduce the selection pressure for resistant bacteria [6].
* Monitoring the effectiveness of treatment: Stewardship programs can monitor the outcomes of tigecycline therapy and provide feedback to prescribers about the appropriateness of their prescribing practices [7].

In summary, stewardship programs can help limit tigecycline resistant infections by promoting the appropriate use of this antibiotic. These programs can encourage the use of alternative antibiotics, limit the duration of therapy, and monitor the effectiveness of treatment, which can help reduce the development of antibiotic resistance.

Sources:

1. DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Centers for Disease Control and Prevention. (2021). Antibiotic Resistance Threats in the United States, 2019. Retrieved from <https://www.cdc.gov/drugresistance/biggest-threats.html>.
3. World Health Organization. (2019). Antimicrobial stewardship: a practical guide. Retrieved from <https://www.who.int/publications/i/item/9789240010335>.
4. Centers for Disease Control and Prevention. (2021). Core Elements of Hospital Antibiotic Stewardship Programs. Retrieved from <https://www.cdc.gov/antibiotic-use/core-elements/hospitals.html>.
5. Fishman, N. O. (2018). Tigecycline: an update on its use and resistance. Expert Opinion on Pharmacotherapy, 19(12), 1281-1289.
6. Grossman, E. C., & Liu, C. C. (2018). Antibiotic stewardship in the intensive care unit. Critical Care Medicine, 46(5), 911-918.
7. Dellit, T. H., Owens, R. C., McGowan, J. E., & Cardona, J. (2007). Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clinical Infectious Diseases, 44(2), 159-177.